000 01615 a2200457 4500
005 20250514162431.0
264 0 _c20040805
008 200408s 0 0 eng d
022 _a1424-8832
024 7 _a10.1159/000073849
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aWolzt, Michael
245 0 0 _aEffects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.
_h[electronic resource]
260 _bPathophysiology of haemostasis and thrombosis
_c
300 _a68-74 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAtrial Fibrillation
_xblood
650 0 4 _aAzetidines
_xadministration & dosage
650 0 4 _aBenzylamines
650 0 4 _aBlood Coagulation Tests
650 0 4 _aCase-Control Studies
650 0 4 _aFemale
650 0 4 _aGlycine
_xanalogs & derivatives
650 0 4 _aHemorrhage
_xchemically induced
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aP-Selectin
_xbiosynthesis
650 0 4 _aPlatelet Activation
_xdrug effects
650 0 4 _aThrombin
_xantagonists & inhibitors
650 0 4 _aThrombosis
_xdrug therapy
700 1 _aBoström, Stig L
700 1 _aSvensson, Mia
700 1 _aWåhlander, Karin
700 1 _aGrind, Margaretha
700 1 _aSarich, Troy C
773 0 _tPathophysiology of haemostasis and thrombosis
_gvol. 33
_gno. 2
_gp. 68-74
856 4 0 _uhttps://doi.org/10.1159/000073849
_zAvailable from publisher's website
999 _c14360798
_d14360798